Get the Stockscreener App
4.605
0.97%
-0.045
Molecular Partners Ag Adr stock is traded at $4.605, with a volume of 918.
It is down -0.97% in the last 24 hours and up +11.50% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
See More
Previous Close:
$4.65
Open:
$4.45
24h Volume:
918
Relative Volume:
0.17
Market Cap:
$172.22M
Revenue:
$7.80M
Net Income/Loss:
$-69.02M
P/E Ratio:
-2.1506
EPS:
-2.1413
Net Cash Flow:
$-66.61M
1W Performance:
-2.02%
1M Performance:
+11.50%
6M Performance:
+29.44%
1Y Performance:
-6.40%
1-Day Range:
$4.45
$4.605
1-Week Range:
$4.45
$4.74
52-Week Range:
$3.36
$5.10
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
4.605 | 173.91M | 7.80M | -69.02M | -66.61M | -2.1413 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | H.C. Wainwright | Buy |
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready - Yahoo Finance
Research Analysts Offer Predictions for MOLN FY2025 Earnings - Defense World
Brokers Offer Predictions for MOLN FY2025 Earnings - MarketBeat
What is HC Wainwright's Estimate for MOLN Q1 Earnings? - MarketBeat
Molecular Partners stock initiated with Buy rating at H.C. Wainwright By Investing.com - Investing.com India
Molecular Partners stock initiated with Buy rating at H.C. Wainwright - Investing.com
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 17.9% in December - MarketBeat
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update - MarketBeat
Molecular Partners (NASDAQ:MOLN) Trading Up 3.1% – Here’s What Happened - Defense World
Molecular Partners (NASDAQ:MOLN) Trading Up 3.1%Here's What Happened - MarketBeat
Molecular Partners (NASDAQ:MOLN) Price Target Cut to $3.75 by Analysts at JPMorgan Chase & Co. - Defense World
Molecular Partners (NASDAQ:MOLN) Trading Down 2.2%What's Next? - MarketBeat
EBITDA per share of Molecular Partners AG Sponsored ADR – TRADEGATE:6ML0 - TradingView
Molecular Partners (NASDAQ:MOLN) Stock Price Down 2.1% – Here’s What Happened - Defense World
Molecular Partners AG (MOLNZ.XC) Stock Price, News, Quote & History - Yahoo
Molecular Partners (NASDAQ:MOLN) Trading 1.5% HigherHere's What Happened - MarketBeat
Liminatus Pharma (LIMN) Short Interest Ratio and Volume 2025 - MarketBeat
Molecular Partners (NASDAQ:MOLN) Price Target Cut to $4.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Leerink Partnrs Has Bullish Estimate for MOLN Q3 Earnings - MarketBeat
Leerink Partnrs Issues Positive Outlook for MOLN Earnings - Defense World
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners Ag shares rise 3.64% intraday after Voyager Therapeutics expands Alzheimer's disease franchise. - AInvest
Molecular Partners and Orano Med Present Promising Preclinical Data on MP0726, a Radio-DARPin Candidate for Ovarian Cancer Treatment - AInvest
Molecular Partners shares rise 1.93% after-hours after presenting positive data from ongoing Phase 1/2A trial. - AInvest
Molecular Partners Ag shares rise 6.71% intraday after MIT and Recursion release Boltz-2 AI model. - AInvest
US NYSE/NASD Stock Directory - Minichart
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com Nigeria
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Molecular Partners (MOLN) Stock Trends and Sentiment 2025 - MarketBeat
Molecular Partners (MOLN) Stock Forecast and Price Target 2026 - MarketBeat
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting By Investing.com - Investing.com South Africa
Skye Bioscience (SKYE) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Stock Market News Today - Stock Titan
Stock Ratings and Recommendations: Understanding Analyst Ratings - MarketBeat
MAIA Biotechnology (MAIA) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
What is the current Price Target and Forecast for Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 - Novartis
Molecular Partners (MOLN) 10K Form and SEC Filings 2025 - MarketBeat
Evaxion A/S (EVAX) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
MOLNMolecular Partners AG ADR Stock Price and Quote - Finviz
Citi Appointed as Depositary Bank for Molecular Partners AG’s ADR Programme - Business Wire
Molecular Partners AG Sponsored ADR (MOLN) - Zacks Investment Research
Molecular Partners (MOLN) Earnings Date and Reports 2026 - MarketBeat
Molecular Partners (MOLN) Competitors and Alternatives 2025 - MarketBeat
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):